Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer

Published:2024 Issue:2 Volume:65 Page:132
ISSN:2466-0493
Container-title:Investigative and Clinical Urology
language:en
Short-container-title:Investig Clin Urol

Author:

Lee Jun Nyung¹^ORCID,Kim Mi Young²^ORCID,Kang Jae Hoon¹^ORCID,Kang Jun-Koo¹^ORCID,Chung Jae-Wook¹^ORCID,Ha Yun-Sok¹^ORCID,Choi Seock Hwan¹^ORCID,Kim Bum Soo¹^ORCID,Kim Hyun Tae¹^ORCID,Kim Tae-Hwan¹^ORCID,Yoo Eun Sang¹^ORCID,Kim See Hyung³^ORCID,Kwon Tae Gyun¹^ORCID

Affiliation:

1. Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.

2. Department of Radiation Oncology, Kyungpook National University Chilgok Hospital, Daegu, Korea.

3. Department of Radiology, School of Medicine, Kyungpook National University, Daegu, Korea.

Funder

National Research Foundation of Korea

Korean Fund for Regenerative Medicine

Publisher

XMLink

Link

https://icurology.org/pdf/10.4111/icu.20230337

Reference20 articles.

1. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

2. Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer

3. Integrating stereotactic body radiation therapy (SBRT) and systemic treatments in oligoprogressive prostate cancer: new evidence from the literature

4. Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer

5. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial